$94.07-1.78 (-1.86%)
Unum Group, together with its subsidiaries, provides financial protection benefit solutions in the United States, the United Kingdom, and Poland.
Unum Group in the Financial Services sector is trading at $94.07 with a market capitalization of $14.8B. Wall Street consensus targets $101.85 (13 analysts), implying a +8.3% move over the next 12 months. The stock is currently near its 52-week high of $96.77, remaining 17.0% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 65/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $3.35B↑ | $3.33B↑ | $3.21B↓ | $3.36B↑ | $3.35B |
| Gross Profit | — | — | — | — | — |
| Operating Income | $382.80M↑ | $355.80M↑ | $271.00M↑ | $106.70M↓ | $469.00M |
| Net Income | $256.90M↑ | $232.00M↑ | $174.10M↑ | $39.70M↓ | $335.60M |
Unum Group, together with its subsidiaries, provides financial protection benefit solutions in the United States, the United Kingdom, and Poland. It operates through Unum US, Unum International, Colonial Life, and Closed Block segments. The company o...

Unum Group currently trades at $96.56 and has been a dream stock for shareholders. It’s returned 268% since September 2021, blowing past the S&P 500’s 69.5% gain. The company has also beaten the index over the past six months as its stock price is up 31.6%.

Unum (UNM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

UNM's new $1 billion buyback authorization reinforces shareholder returns, backed by strong capital and recurring repurchases.

As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the life insurance industry, including Unum Group (NYSE:UNM) and its peers.

GL's premium growth, rising investment income and AI initiatives support earnings, while higher health claims remain a risk.